According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey. At least 16 of the upcoming cancer drugs are genetically engineered. Since many of these drugs are targeted to more than one type of cancer, 223 research projects are ongoing.